Freezing spray before chemo for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a freezing spray (cryotherapy) to shrink esophageal tumors before standard chemotherapy. It may help reduce tumor size and improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called adenocarcinoma that has spread to nearby lymph nodes or deeper layers but not to other organs.
- You are expected to receive a chemotherapy regimen called FLOT, possibly with an immunotherapy drug called durvalumab.
- You have a tumor stage defined as T1N+M0 or T2-T4aNanyM0.
- You are 18 years or older.
- You do not have a bleeding disorder or low platelet count.
- You are able to have a tube placed through your mouth into your stomach for the procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs given together with radiation therapy, followed by additional chemotherapy, for newly diagnosed adenocarcinoma (a type of cancer) in the esophagus or where the esophagus meets the stomach. The goal is to shrink the tumor and improve survival.
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
This trial tests a combination of three drugs (penpulimab, anlotinib, and chemotherapy) given before surgery to shrink esophageal cancer. It is for people with locally advanced cancer who have not had treatment before.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests whether giving chemotherapy combined with immunotherapy before surgery works better than the standard chemoradiation for esophageal cancer that can be removed. It may help reduce tumor size and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.